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Abstract: To evaluate the predictive and prognostic significance of the
prognostic nutritional index (PNI) in a large cohort of gastric cancer
patients who underwent gastrectomy.
Assessing a patient’s immune and nutritional status, PNI has been
reported as a predictive marker for surgical outcomes in various types of
cancer.
We retrospectively reviewed data from a prospectively maintained
database of 7781 gastric cancer patients who underwent gastrectomy
from January 2001 to December 2010 at a single center. From this data,
we analyzed clinicopathologic characteristics, PNI, and short- and long-
term surgical outcomes for each patient. We used the PNI value for the
10th percentile (46.70) of the study cohort as a cut-off for dividing
patients into low and high PNI groups.
Regarding short-term outcomes, multivariate analysis showed a low
PNI (odds ratio [OR]¼ 1.505, 95% CI¼ 1.212–1.869, P<0.001), old
age, male sex, high body mass index, medical comorbidity, total
gastrectomy, and combined resection to be independent predictors of
postoperative complications. Among these, only low PNI (OR¼ 4.279,
95% CI¼ 1.760–10.404, P¼ 0.001) and medical comorbidity weree-Ho Cheong, MD, g, MD,
Choong-Bai Kim, MD
CI¼ 1.221–1.568, P< 0.001; recurrence-free survival: HR¼ 1.142,
95% CI¼ 0.985–1.325, P¼ 0.078).
PNI can be used to predict patients at increased risk of postoperative
morbidity and mortality. Although PNI was an independent prognostic
factor for overall survival, the index was not associated with cancer
recurrence.
(Medicine 95(18):e3539)
Abbreviations: ASA = American Society of Anesthesiologists,
AUC = area under the curve, BMI = body mass index, CI =
confidence interval, HR = hazard ratio, iAUC = integrated area under
the curve, OR = odds ratio, PNI = prognostic nutritional index.
INTRODUCTION
S uccessful treatment of gastric cancer largely depends on asuccessful gastrectomy. While this surgery can potentially
cure the disease, it also harbors the risk of perioperative
morbidity and mortality. Perioperative complication rates
during gastric cancer surgery range from 10% to 46%,1–4
and adversely affect long-term survival.5,6 As gastric cancer
is the fifth most common malignancy worldwide,7 improving
short- and long-term surgical outcomes for patients with gastric
cancer is of great necessity.
Researchers have spent great effort to identify factors
related to adverse surgical outcomes and prognosis. Several
factors, including medical comorbidity, old age, combined
resection, and advanced stage, are associated with surgical
outcomes and hold prognostic significance8–10; however, these
factors are primarily unamenable, as they are related to the
patient’s physical or disease status. Thus, assessments of nutri-
tional status have emerged as potential prognostic factors, since
nutritional status can be corrected prior to surgery. While
several tools for assessing nutritional status have been evalu-
ated, including the nutritional risk index,11 the nutritional risk
screening 2002,12 and subjective global assessment,13,14 these
are difficult to use in daily clinical practice due to their
complexity. Moreover, some of the parameters used by these
tools are not always available, for example changes in weight.
Unlike other assessments, the prognostic nutritional index
(PNI) can be easily calculated using the following equation:
[(10 serum albumin (g/dL))þ (0.005 total lymphocyte
count)].15 The parameters used by this index are routinely
evaluated in laboratory tests during preoperative diagnosticrepeat. The predictive value of the PNI
s widely accepted in various solid organ
hageal, colorectal, liver, and pancreatic
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cancer.16–19 However, only a few reports have evaluated the
significance of PNI in predicting short- and long-term surgical
outcomes for patients with gastric cancer,20,21 and a comprehen-
sive study has never been conducted. Furthermore, controversy
exists regarding the optimal cut-off values for PNI in predicting
short- and long-term surgical outcomes.
Accordingly, the aim of this study was to assess the value of
PNI as a predictor of perioperative morbidity and mortality, as
well as a prognostic factor for recurrence-free and overall survi-
val. Additionally, we also compared the performance of a single
cut-off valuebasedonpercentiles ofPNI to statistically optimized
cut-off values of PNI for individually predicting morbidity,
mortality, recurrence-free survival, and overall survival.
METHODS
Lee et alPatients
In the present study, we retrospectively reviewed and
analyzed data from medical records stored in a prospectively
TABLE 1. Demographics of Patients According to PNI Group
Whole Coho
n (%); Total¼
Age group <60 4157 (53.4%
60 3624 (46.6%
Age 57.1 11.9
Sex Male 5150 (66.2%
Female 2631 (33.8%
Body mass index

23.2 3
Medical comorbidity No 4415 (56.7%
Yes 3366 (43.3%
ASA score 1 4327 (56.7%
2 3078 (40.4%
3 218 (2.9%
4 3 (0%)
Lymphocytes

2125.1 663
Albumin

4.4 0.4
PNI value

54.2 5.9
Extent of gastric resection Subtotal gastrectomy 5895 (75.8%
Total gastrectomy 1886 (24.2%
Combined resectiony No 7501 (96.4%
Yes 280 (3.6%
Operation time

164.3 53.
Tumor size

37.2 26.6
T classification T1 4182 (53.8%
T2 944 (12.1%
T3 913 (11.7%
T4a 1700 (21.9%
T4b 42 (0.5%
N classification N0 4967 (63.8%
N1 941 (12.1%
N2 798 (10.3%
N3 1075 (13.8%
Stage I 4608 (59.2%
II 1286 (16.5%
III 1887 (24.3%
PNI¼ prognostic nutritional index.
Student t test; results indicate mean standard deviation.
ySimultaneous resection of the gallbladder owing to stone formation wa
2 | www.md-journal.commaintained database. Our study included 8811 consecutive
patients with histologically confirmed gastric adenocarcinoma
who underwent gastrectomy at Severance Hospital between
January 2001 and December 2010. We excluded 1030 patients
with a history of other primary cancer, neoadjuvant chemother-
apy, radiotherapy, noncurative resection, or emergency surgery
due to perforation, bleeding, or obstruction. The remaining 7781
patients were included for analysis. The Institutional Review
Board of Severance Hospital approved this study and waived the
need for written informed consent from the participants (4-
2015-0085).
Clinicopathological characteristics included age, sex, pre-
operative body mass index (BMI), medical comorbidities,
American Society of Anesthesiologists (ASA) score, tumor
size, and pathological stage. A medical comorbidity was
defined as a preexisting medical condition that needed long-
Medicine  Volume 95, Number 18, May 2016term treatment. Perioperative data were also noted, including
the extent of resection, combined resection, and operation time.
Surgical resection and extent of lymphadenectomy were
rt,
7781
Low PNI,
n (%); Total¼ 779
High PNI,
n (%); Total¼ 7002 P Value
) 245 (31.5%) 3912 (55.9%) <0.001
) 534 (68.5%) 3090 (44.1%)
63.2 11.1 56.4 11.8 <0.001
) 522 (67.0%) 4628 (66.1%) 0.609
) 257 (33.0%) 2374 (33.9%)
22.1 2.9 23.4 2.9 <0.001
) 397 (50.9%) 4018 (57.4%) 0.001
) 382 (49.1%) 2984 (42.6%)
) 323 (42.4%) 4004 (58.3%) <0.001
) 382 (50.1%) 2696 (39.3%)
) 55 (7.2%) 163 (2.4%)
2 (0.3%) 1 (0%)
.8 1453.9 454.2 2199.8 641.1 <0.001
3.6 0.4 4.5 0.3 <0.001
42.8 3.8 55.5 4.5 <0.001
) 521 (66.9%) 5374 (76.8%) <0.001
) 258 (33.1%) 1628 (23.2%)
) 714 (91.7%) 6787 (96.9%) <0.001
) 65 (8.3%) 215 (3.1%)
2 166.1 51.1 164.1 53.4 0.317
58.2 33.6 34.8 24.6 <0.001
) 198 (25.4%) 3984 (56.9%) <0.001
) 91 (11.7%) 853 (12.2%)
) 133 (17.1%) 780 (11.1%)
) 347 (44.5%) 1353 (19.3%)
) 10 (1.3%) 32 (0.5%)
) 300 (38.5%) 4667 (66.7%) <0.001
) 124 (15.9%) 817 (11.7%)
) 124 (15.9%) 674 (9.6%)
) 231 (29.7%) 844 (12.1%)
) 233 (29.9%) 4375 (62.5%) <0.001
) 170 (21.8%) 1116 (15.9%)
) 376 (48.3%) 1511 (21.6%)
s not considered a combined resection.
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using SAS software (version 9.2; SAS Institute, Cary, NC) andperformed in accordance with the Japanese guidelines for
treating gastric cancer.22 Adverse events occurring within 30
days after surgery or during hospitalization were classified as
postoperative complications or mortality; the type of compli-
cation was recorded. Patient staging was adjusted according to
the 7th edition of the American Joint Committee on Cancer
staging system.23 Follow-up evaluations were performed
according to a fixed schedule: every 3 months for 2 years,
and then every 6 months for 3 years thereafter. Follow-up
evaluations comprised clinical and laboratory examinations
with biannual imaging and annual endoscopic evaluation.
Patients with stage II or higher disease were recommended
to receive 5-fluorouracil-based adjuvant chemotherapy.
Prognostic Nutritional Index and Patient
Grouping
We obtained laboratory data, including serum albumin
levels and lymphocyte counts, from baseline workup conducted
within 2 months before surgery. The PNI was calculated by the
following equation: [(10 serum albumin (g/
dL))þ (0.005 total lymphocyte count)]. First, we divided
patients according to every 5th percentile of PNI into 20 groups
(389 patients in each group). From the 5th to 100th percentiles,
the mortality events in each group were: 3, 5, 2, 1, 0, 1, 3, 0, 0, 1,
0, 1, 0, 0, 1, 0, 2, 0, 1, and 1, respectively. The complication rates
for each of these groups were: 18.0%, 17.2%, 11.1%, 10.2%,
12.3%, 12.8%, 9.8%, 12.3%, 10.0%, 7.2%, 11.1%, 9.5%, 9.9%,
9.4%, 10.7%, 13.3%, 11.2%, 10.8%, 9.3%, and 11.90%,
respectively. As the 10th percentile of PNI showed the highest
morbidity and mortality, we used its value as a cut-off to divide
patients into 2 groups: higher or lower than the PNI value for the
10th percentile. We hypothesized that this value would be more
practical than median or mean values and could better identify
patients at high risk for perioperative morbidity, as well as those
who may benefit from nutritional interventions prior to surgery.
Statistical Analysis
Categorical variables were compared using the x2 test, and
Medicine  Volume 95, Number 18, May 2016continuous variables were compared using Student t test. We
used Youden indices to determine the optimal PNI cut-off
values to maximize sensitivity and specificity for complications
TABLE 2. Performance of the 10th Percentile Value in Compariso
Short-Term
Surgical Outcomes
Lon
AUC (95% CI) P Value

Overall complications Recu
Below the 10th
percentile (46.7)
0.530 (0.518–0.542) 0.590 Belo
pe
Youden index (51.52) 0.534 (0.517–0.550) Cont
m
Mortality Over
Below the 10th
percentile (46.7)
0.632 (0.529–0.735) 0.608 Belo
pe
Youden index (52.18) 0.657 (0.554–0.760) Cont
m
AUC¼ area under the curve; CI¼ confidence interval; iAUC¼ integrate
Differences in AUC were calculated using the Delong method.25
yDifferences in iAUC were calculated using a bootstrapping method wit
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.and mortality.24 Comparison of the area under ROC the curve
(AUC) was performed as recommended by DeLong et al.25
Overall survival was defined as the duration of time from
the date of surgery until the date of patient death. Recurrence-
free survival was defined as the duration of time from the date of
surgery until the date of histologic or radiologic recurrence of
gastric cancer. To find the optimal cut-off PNI values for overall
and recurrence-free survival, we used the Contal and O’Quigley
method, which is based on the concept of maximizing the log-
rank statistic.26We then compared the integrated areas under the
curve (iAUC) between the model divided according to the 10th
percentile and the models divided according to the optimized
cut-off values determined using the Contal and O’Quigley
method. iAUC is a weighted average of the AUC across a
follow-up period and is a measure of the predictive accuracy of a
model during follow-up. A higher iAUC indicates a better
predictive accuracy. Differences in iAUC were calculated using
a bootstrapping method with 1000 resampling times.27
All P values less than 0.05 were regarded as significant,
and all statistical tests were 2-sided. Analyses were conducted
PNI in Gastric CancerR software (version 2.13.1; R Foundation for Statistical Com-
puting, Vienna, Austria).
RESUTLS
Patient Demographics and Comparison of the
Low and High PNI Groups
Table 1 lists the clinical, laboratory, operative, and patho-
logic characteristics of the entire cohort and compares the
characteristics for the low versus the high PNI group. Among
the entire cohort, 3624 were older than 60 years (46.6%); 5150
were male (66.2%); the mean BMI was 23.2  3; and 3366 had
a medical comorbidity (43.3%). Subtotal and total gastrec-
tomies were performed in 5895 (75.8%) and 1886 (24.2%)
patients, respectively. Combined resection was performed in
280 patients (3.6%). Stage I, II, and III disease was found in
4608 (59.2%), 1286 (16.5%), and 1887 (24.3%) patients,
respectively. The mean PNI was 54.2  5.9.
Grouping patients according to the PNI value of 46.70, we
found that low PNI was associated with old age, low BMI,
n With Statistically Optimized Cut-Off Values of PNI
g-Term Surgical Outcomes
iAUC
(95% CI)
DAUCy
(D 95% CI)
rrence-free survival
w the 10th
rcentile (46.7)
0.551
(0.541–0.562)
0.034
(0.021–0.046)
al and O’Quigley
ethod (53.22)
0.585
(0.571–0.599)
all survival
w the 10th
rcentile (46.7)
0.566
(0.555–0.579)
0.029
(0.014–0.042)
al and O’Quigley
ethod (52.36)
0.596
(0.581–0.609)
d area under the curve; PNI¼ prognostic nutritional index.
h 1000 resampling times.27
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medical comorbidity, a higher ASA score, low lymphocyte
counts, and low albumin levels. The mean age of the patients
with low and high PNI was 63.2 11.1 and 56.4 11.8,
respectively. Operative parameters showed more frequent
association between patients with a low PNI and total gastrect-
omy or combined resection than those with a high PNI. Patients
with low PNI also had larger tumors, more advanced T and N
classifications, and more advanced disease stage.
Comparison Between the 10th Percentile and
Statistically Optimized Cut-Off Values of PNI
Using AUC values, we compared the performance of the
10th percentile PNI value versus statistically optimized PNI cut-
off values to assess overall complications, mortality, recur-
rence-free survival, and overall survival (Table 2). For short-
term surgical outcomes, the optimal cut-off values determined
Lee et alusing Youden’s method for morbidity (PNI¼ 51.52) and
mortality (PNI¼ 52.18) had higher AUCs than that of the
10th percentile value (PNI¼ 46.70). However, no statistical
TABLE 3. Short-Term Surgical Outcomes According to PNI Grou
Low PNI, n (%); Tota
Hospital stay

12 10.8
Overall complications No 642 (82.4%)
Yes 137 (17.6%)
Wound No 737 (94.6%)
Yes 42 (5.4%)
Abscess No 748 (96%)
Yes 31 (4%)
Intra-abdominal bleeding No 774 (99.4%)
Yes 5 (0.6%)
Intraluminal bleeding No 771 (99%)
Yes 8 (1%)
Intestinal obstruction No 758 (97.3%)
Yes 21 (2.7%)
Stenosisy No 777 (99.7%)
Yes 2 (0.3%)
Leakage No 765 (98.2%)
Yes 14 (1.8%)
Pulmonary complication No 754 (96.8%)
Yes 25 (3.2%)
Urinary complicationy No 775 (99.5%)
Yes 4 (0.5%)
Renal complicationy No 775 (99.5%)
Yes 4 (0.5%)
Hepatic complicationy No 776 (99.6%)
Yes 3 (0.4%)
Cardiac complication No 773 (99.2%)
Yes 6 (0.8%)
Endocrine complicationy No 779 (100%)
Yes 0 (0%)
Stasisy No 777 (99.7%)
Yes 2 (0.3%)
Pancreas complicationy No 775 (99.5%)
Yes 4 (0.5%)
Mortality No 771 (99%)
Yes 8 (1%)
PNI¼ prognostic nutritional index.
Student t test; results indicate mean standard deviation.
yFisher exact test.
4 | www.md-journal.comdifference was observed for the prediction of an event. Regard-
ing long-term surgical outcomes, the optimal cut-offs deter-
mined by the Contal and O’Quigley method for recurrence-free
survival (PNI¼ 53.22) and overall survival (PNI¼ 52.36) had
higher iAUCs with statistically better predictive power (recur-
rence-free survival: DAUC¼ 0.034, 95% CI¼ 0.021–0.046;
overall survival: DAUC¼ 0.029, 95% CI¼ 0.014–0.042) than
that of the 10th percentile value.
Short-Term Surgical Outcomes
Patients in the low PNI group remained in the hospital
longer than those in the high PNI group (Table 3). The overall
complication and mortality rates for the entire cohort were
11.4% and 0.3%, respectively. Compared with the high PNI
group, the low PNI group showed significantly higher compli-
cation rates (10.7% versus 17.6%, respectively; P< 0.001) and
Medicine  Volume 95, Number 18, May 2016mortality rates (0.2% versus 1%, respectively; P< 0.001). The
low PNI group had higher rates of wound infection, abscess
formation, intraluminal bleeding, intestinal obstruction, and
p
l¼ 779 High PNI, n (%); Total¼ 7002 P Value
9.3 7.9 <0.001
6251 (89.3%) <0.001
751 (10.7%)
6728 (96.1%) 0.047
274 (3.9%)
6833 (97.6%) 0.009
169 (2.4%)
6975 (99.6%) 0.246
27 (0.4%)
6984 (99.7%) 0.003
18 (0.3%)
6907 (98.6%) 0.003
95 (1.4%)
6987 (99.8%) 0.685
15 (0.2%)
6937 (99.1%) 0.022
65 (0.9%)
6856 (97.9%) 0.042
146 (2.1%)
6983 (99.7%) 0.281
19 (0.3%)
6995 (99.9%) 0.019
7 (0.1%)
6998 (99.9%) 0.026
4 (0.1%)
6980 (99.7%) 0.055
22 (0.3%)
6996 (99.9%) 0.999
6 (0.1%)
6997 (99.9%) 0.150
5 (0.1%)
6969 (99.5%) 0.784
33 (0.5%)
6988 (99.8%) <0.001
14 (0.2%)
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
leakage than the high PNI group. Complications associated with
pulmonary, renal, hepatic, and cardiac organs also were
observed frequently in the low PNI group. Logistic regression
analysis revealed that low PNI (odds ratio [OR]¼ 1.505, 95%
CI¼ 1.212–1.869, P< 0.001), old age, male sex, high BMI,
medical comorbidity, total gastrectomy, and combined resec-
tion were independent risk factors for overall complications
Medicine  Volume 95, Number 18, May 2016(Table 4). Only low PNI (OR¼ 4.279, 95%CI¼ 1.760–10.404,
P¼ 0.001) and medical comorbidity were independent risk
factors for mortality.
TABLE 4. Univariate and Multivariate Analyses of Short- and Lon
Short-Term Surgical Outcome
Overall Complications
Univariate Multivariate
OR 95% CI P Value OR 95% CI P Va
Age (60/<60) 1.637 1.422–1.886 <0.001 1.402 1.206–1.630 <0.0
Sex (male/female) 1.355 1.161–1.582 <0.001 1.288 1.099–1.510 0.0
Body mass index 1.049 1.025–1.074 <0.001 1.053 1.028–1.080 <0.0
Medical
comorbidity
(yes/no)
1.693 1.471–1.949 <0.001 1.516 1.304–1.762 <0.0
PNI (low/high) 1.776 1.444–2.168 <0.001 1.505 1.212–1.869 <0.0
Gastrectomy
(total/subtotal)
2.320 2.005–2.684 <0.001 2.042 1.735–2.403 <0.0
Combined
resection
(yes/no)
3.190 2.432–4.184 <0.001 1.923 1.422–2.601 <0.0
Tumor size
(30 mm/<30)
1.427 1.241–1.642 <0.001 1.113 0.933–1.328 0.2
Stage <0.001 0.8
II/I 1.191 0.979–1.448 0.080 0.979 0.79–1.214 0.6
III/I 1.558 1.328–1.828 <0.001 1.048 0.852–1.289 0.5
Mortality
Univariate Multivariate
OR 95% CI P Value OR 95% CI
Age (60/<60) 3.068 1.199–7.849 0.019 1.5620.594–4.106
Sex (male/female) 1.739 0.641–4.720 0.277
Body mass index 1.006 0.870–1.163 0.937
Medical
comorbidity
(yes/no)
13.189 3.081–56.465 0.001 11.220 2.578–48.834
PNI (low/high) 5.179 2.166–12.385 <0.001 4.2791.760–10.404
Gastrectomy
(total/subtotal)
2.170 0.926–5.083 0.075
Combined
resection
(yes/no)
2.691 0.626–11.57 0.183
Tumor size
(30 mm/<30)
0.986 0.425–2.285 0.973
Stage 0.185
II/I 0.651 0.144–2.941 0.577
III/I 2.003 0.829–4.841 0.123
CI¼ confidence interval; HR¼ hazard ratio; OR¼ odds ratio; PNI¼ pro
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Long-Term Surgical Outcomes
In the recurrence-free survival analysis, patients in the low
PNI group had a poor prognosis (Figure 1A; P< 0.001). How-
ever, after stratifying patients according to disease stage, we
found no significant differences between the low and high PNI
groups in recurrence-free survival for patients with stage I or
PNI in Gastric Cancerstage II disease (Figure 1B–D; stage I, P¼ 0.098; II, P¼ 0.076;
III, P¼ 0.020). Further stratifying stage III into stages IIIa, IIIb,
and IIIc also revealed no significant survival differences
g-Term Surgical Outcomes
Long-Term Surgical Outcome
Recurrence-Free Survival
Univariate Multivariate
lue HR 95% CI P Value HR 95% CI P Value
01 1.155 1.035–1.289 0.010 1.105 0.987–1.237 0.083
02 1.027 0.915–1.154 0.649
01 0.936 0.918–0.954 <0.001 0.98 0.962–0.999 0.040
01 0.927 0.829–1.037 0.183
01 2.430 2.110–2.798 <0.001 1.142 0.985–1.325 0.078
01 2.540 2.272–2.840 <0.001 1.194 1.056–1.351 0.005
01 5.168 4.354–6.133 <0.001 1.592 1.319–1.921 <0.001
34 5.745 4.998–6.603 <0.001 1.357 1.157–1.592 <0.001
27 <0.001 <0.001
54 6.620 5.33–8.224 <0.001 5.846 4.65–7.351 <0.001
48 25.404 21.134–30.536 <0.001 19.098 15.452–23.604 <0.001
Overall Survival
Univariate Multivariate
P Value HR 95% CI P Value HR 95% CI P Value
0.366 1.821 1.649–2.011 <0.001 1.6781.512–1.863 <0.001
1.174 1.056–1.305 0.003 1.0910.980–1.215 0.112
0.926 0.911–0.942 <0.001 0.9590.943–0.976 <0.001
0.001 1.212 1.099–1.337 <0.001 1.1971.080–1.327 0.001
0.001 2.864 2.544–3.223 <0.001 1.3831.221–1.568 <0.001
2.439 2.207–2.694 <0.001 1.3461.205–1.502 <0.001
4.565 3.899–5.343 <0.001 1.5291.287–1.818 <0.001
4.107 3.668–4.600 <0.001 1.3371.166–1.534 <0.001
<0.001 <0.001
3.090 2.634–3.625 <0.001 2.6052.198–3.087 <0.001
10.389 9.183–11.753 <0.001 7.0866.091–8.244 <0.001
gnostic nutritional index.
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FIGURE 1. Long-term surgical outcomes according to PNI group at each stage of disease. Recurrence-free survival of (A) all stages, (B)
tag
Lee et al Medicine  Volume 95, Number 18, May 2016between the low and high PNI groups (P¼ 0.606, P¼ 0.461,
stage I, (C) stage II, and (D) stage III. Overall survival of (E) all s
PNI¼prognostic nutritional index.and P¼ 0.533, respectively). Applying the optimal PNI value
determined by the Contal and O’Quigley method, recurrence-
free survival still showed no survival difference between low
6 | www.md-journal.comand high PNI groups stratified by disease stage, with the
es, (F) stage I, (G) stage II, and (H) stage III. HR¼hazard ratio;exception of stage Ia (Ia, P¼ 0.008; Ib, P¼ 0.641; IIa,
P¼ 0.251; IIb, P ¼ 0.116; IIIa, P¼ 0.536; IIIb, P¼ 0.099;
and IIIc, P¼ 0.677). Regardless of the cut-off value applied,
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
T
A
B
L
E
5
.
P
e
rf
o
rm
a
n
ce
o
f
th
e
C
u
t-
O
ff
V
a
lu
e
s
A
ft
e
r
A
d
ju
st
m
e
n
t
fo
r
C
o
n
fo
u
n
d
in
g
Fa
ct
o
rs
S
h
or
t-
T
er
m
S
u
rg
ic
al
O
u
tc
om
es
L
on
g-
T
er
m
S
u
rg
ic
al
O
u
tc
om
es
A
d
ju
st
m
en
t
M
od
el
1
M
od
el
2
M
od
el
3
A
d
ju
st
m
en
t
M
od
el
1
M
od
el
2
M
od
el
3
M
od
el
4
O
R
(9
5%
C
I)
P
V
al
u
e
O
R
(9
5%
C
I)
P
V
al
u
e
O
R
(9
5%
C
I)
P
V
al
u
e
H
R
(9
5%
C
I)
P
V
al
u
e
H
R
(9
5%
C
I)
P
V
al
u
e
H
R
(9
5%
C
I)
P
V
al
u
e
H
R
(9
5%
C
I)
P
V
al
u
e
O
v
er
al
l
co
m
p
li
ca
ti
o
n
s
R
ec
u
rr
en
ce
-f
re
e
su
rv
iv
al
B
el
o
w
th
e
1
0
th
p
er
ce
n
ti
le
(4
6
.7
)
1
.7
7
6
(1
.4
5
5
–
2
.1
6
8
)
<
0
.0
0
1
1
.6
8
6
(1
.3
6
9
–
2
.0
7
7
)
<
0
.0
0
1
1
.5
0
1
(1
.2
1
4
–
1
.8
5
6
)
0
.0
0
2
B
el
o
w
th
e
1
0
th
p
er
ce
n
ti
le
(4
6
.7
)
2
.4
3
(2
.1
1
–
2
.7
9
8
)
<
0
.0
0
1
2
.2
9
5
(1
.9
8
7
–
2
.6
5
1
)
<
0
.0
0
1
2
.0
1
4
(1
.7
4
2
–
2
.3
3
)
<
0
.0
0
1
1
.1
6
7
(1
.0
0
9
–
1
.3
5
1
)
0
.0
3
8
Y
o
u
d
en
in
d
ex
(5
1
.5
2
)
1
.3
8
0
(1
.1
9
0
–
1
.6
)
<
0
.0
0
1
1
.3
2
1
(1
.1
3
1
–
1
.5
4
4
)
0
.0
0
5
1
.1
9
2
(1
.0
1
7
–
1
.3
9
7
)
<
0
.0
0
1
C
o
n
ta
l
an
d
O
’Q
u
ig
le
y
m
et
h
o
d
(5
3
.2
2
)
2
.0
3
9
(1
.8
2
6
–
2
.2
7
6
)
<
0
.0
0
1
1
.9
6
6
(1
.7
5
7
–
2
.2
)
<
0
.0
0
1
1
.7
7
4
(1
.5
8
4
–
1
.9
8
7
)
<
0
.0
0
1
1
.0
8
1
(0
.9
6
3
–
1
.2
1
3
)
0
.1
8
5
M
o
rt
al
it
y
O
v
er
al
l
su
rv
iv
al
B
el
o
w
th
e
1
0
th
p
er
ce
n
ti
le
(4
6
.7
)
5
.1
7
9
(2
.1
6
6
–
1
2
.3
8
5
)
<
0
.0
0
1
4
.6
3
1
(1
.9
3
1
–
1
1
.1
0
7
)
<
0
.0
0
1
B
el
o
w
th
e
1
0
th
p
er
ce
n
ti
le
(4
6
.7
)
2
.8
6
4
(2
.5
4
4
–
3
.2
2
3
)
<
0
.0
0
1
2
.2
7
4
(2
.0
0
9
–
2
.5
7
5
)
<
0
.0
0
1
2
.0
7
3
(0
.8
3
2
–
2
.3
4
6
)
<
0
.0
0
1
1
.3
3
7
(1
.1
7
9
–
1
.5
1
6
)
<
0
.0
0
1
Y
o
u
d
en
in
d
ex
(5
2
.1
8
)
3
.6
8
1
(1
.5
4
2
–
8
.7
8
7
)
0
.0
0
3
3
.5
2
5
(1
.4
7
5
–
8
.4
2
5
)
0
.0
0
4
C
o
n
ta
l
an
d
O
’Q
u
ig
le
y
m
et
h
o
d
(5
2
.3
6
)
2
.2
7
1
(2
.0
6
–
2
.5
0
4
)
<
0
.0
0
1
1
.9
0
8
(1
.7
2
2
–
2
.1
1
3
)
<
0
.0
0
1
1
.7
5
1
(1
.5
8
–
1
.9
4
)
<
0
.0
0
1
1
.1
6
4
(1
.0
4
8
–
1
.2
9
3
)
0
.0
0
4
A
d
ju
st
ed
v
ar
ia
b
le
s
fo
r
o
v
er
al
l
co
m
p
li
ca
ti
o
n
s:
M
o
de
l
1
¼
P
N
I
M
o
de
l
2
¼
P
N
I,
ag
e,
se
x
,
B
M
I,
m
ed
ic
al
co
m
o
rb
id
it
y
.
M
o
de
l
3
¼
P
N
I,
ag
e,
se
x
,
B
M
I,
m
ed
ic
al
co
m
o
rb
id
it
y
,
g
as
tr
ec
to
m
y
,
co
m
b
in
ed
re
se
ct
io
n
.
A
d
ju
st
ed
v
ar
ia
b
le
s
fo
r
m
or
ta
li
ty
:
M
o
de
l
1
¼
P
N
I
M
o
de
l
2
¼
P
N
I,
m
ed
ic
al
co
m
o
rb
id
it
y
.
A
d
ju
st
ed
v
ar
ia
b
le
s
fo
r
re
cu
rr
en
ce
-f
re
e
su
rv
iv
al
:
M
o
de
l
1
¼
P
N
I
M
o
de
l
2
¼
P
N
I,
B
M
I
M
o
de
l
3
¼
P
N
I,
B
M
I,
g
as
tr
ec
to
m
y
,
co
m
b
in
ed
re
se
ct
io
n
.
M
o
de
l
4
¼
P
N
I,
B
M
I,
g
as
tr
ec
to
m
y
,
co
m
b
in
ed
re
se
ct
io
n
,
tu
m
o
r
si
ze
,
st
ag
e.
A
d
ju
st
ed
v
ar
ia
b
le
s
fo
r
o
v
er
al
l
su
rv
iv
al
:
M
o
de
l
1
¼
P
N
I
M
o
de
l
2
¼
P
N
I,
ag
e,
B
M
I,
m
ed
ic
al
co
m
o
rb
id
it
y
.
M
o
de
l
3
¼
P
N
I,
ag
e,
B
M
I,
m
ed
ic
al
co
m
o
rb
id
it
y
,
g
as
tr
ec
to
m
y
,
co
m
b
in
ed
re
se
ct
io
n
.
M
o
de
l
4
¼
P
N
I,
ag
e,
B
M
I,
m
ed
ic
al
co
m
o
rb
id
it
y
,
g
as
tr
ec
to
m
y
,
co
m
b
in
ed
re
se
ct
io
n
,
tu
m
o
r
si
ze
,
st
ag
e.
B
M
I¼
b
o
d
y
m
as
s
in
d
ex
;
C
I¼
co
n
fi
d
en
ce
in
te
rv
al
;
H
R
¼
h
az
ar
d
ra
ti
o;
O
R
¼
o
d
d
s
ra
ti
o;
P
N
I¼
p
ro
g
no
st
ic
n
u
tr
it
io
n
al
in
d
ex
.
Medicine  Volume 95, Number 18, May 2016 PNI in Gastric Cancer
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com | 7
PNI was not associated with recurrence-free survival. Using
Cox regression analysis, we found that low BMI, total gas-
trectomy, combined resection, larger tumor size, and stage of
disease were independent risk factors of recurrence-free survi-
val (Table 4). Low PNI was not an independent risk factor for
recurrence-free survival (hazard ratio [HR]¼ 1.142, 95%
CI¼ 0.985–1.325, P¼ 0.078).
In the overall survival analysis, the low PNI group had a
poor prognosis for all stages of disease (Figure 1E–H; for all
stages and stages I, II, and III: P< 0.001). Independent risk
factors for overall survival included low PNI (HR¼ 1.383, 95%
CI¼ 1.221–1.568, P< 0.001), old age, low BMI, medical
comorbidity, total gastrectomy, combined resection, larger
tumor size, and disease stage.
Comparison After Adjustment for Confounding
Factors
To account for confounding factors in evaluating the
performance of each cut-off value, we applied a stepwise
adjustment for confounding factors to develop models for short-
and long-term surgical outcomes (Table 5). Both the 10th
percentile cut-off value and the statistically optimized cut-off
values showed robustness after adjusting for confounding vari-
ables. Interestingly, the 10th percentile value showed higher
odds ratios and hazard ratios with more statistical significance
than the statistically optimized cut-off values for mortality,
recurrence-free survival, and overall survival.
DISCUSSION
The present study retrospectively analyzed individual
clinical data from 7781 patients who underwent curative resec-
tion for gastric cancer at a high-volume center in Korea.
Selecting the 10th percentile PNI value as a cut-off, we found
that patients with a PNI lower than 46.70 show significantly
higher overall morbidity and mortality than those with a higher
PNI. Low PNI also was associated with unfavorable overall
survival; recurrence-free survival was not correlated with PNI.
In the literature, various cut-off values for PNI have been
suggested, including 49.7,28 48,21 and 44.7.20 In our study, we
used the 10th percentile PNI value (46.70) and statistically
optimized values as cut-offs for overall complications (51.52,
the 28.4th percentile), mortality (52.18, the 32.3rd percentile),
recurrence-free survival (53.22, the 39.6th percentile), and
overall survival (52.36, the 33.4th percentile). Clinically, a
cut-off value higher than the 10th percentile value, including
median or mean values, would not be useful, as too many
patients would be categorized as high risk. In this study,
patients with a PNI value in the 10th percentile showed a
mortality rate 5 times higher than that of other patients. As
strength of our study, we were able to validate the use of PNI to
predict mortality, which is an extremely rare event, in a very
large cohort. Additionally, we successfully demonstrated the
robustness of the 10th percentile PNI value in comparison to
optimal cut-off values for individual short- and long-term
surgical outcomes.
Numerous prospective studies of perioperative nutritional
support have failed to reveal improvements in short-term
surgical outcomes as a result thereof.29–31 Thus, it is likely
that only severely malnourished patients benefit from preopera-
tive nutritional support.31–33 If malnutrition affects postopera-
Lee et altive results and a clinically applicable parameter becomes
available, interventions to improve nutritional status prior to
surgery could become attractive targets to optimize patient
8 | www.md-journal.comoutcomes. Since it is unknown whether PNI could serve as a
nutritional parameter to select candidates for nutritional inter-
vention, prospective validation of nutritional intervention in
patients with low PNI should be performed in the future.
Regarding long-term surgical outcomes, our study showed
that PNI was an independent risk factor for overall survival, but
not for recurrence-free survival. Since our findings on recur-
rence-free survival do not corroborate those of a previous
study,21 we extensively validated the prognostic significance
of PNI. For further validation, we examined the performance of
the 10th percentile cut-off value in comparison to optimal cut-
off values derived from statistical tests. In doing so, we found
that low PNI is indeed not a significant prognostic factor for
recurrence-free survival in subgroup analysis stratifying
patients by disease stage or in multivariate Cox analysis.
Therein, the prognostic impact of PNI on recurrence-free
survival decreased and disappeared after adjusting for con-
founding factors. Additionally, although PNI was significantly
associated with overall survival, an age difference of 7 years
(63.2 vs. 56.4) between the 2 groups may have affected the
survival analysis results, despite adjusting for age in the stat-
istical models. Contrary to previous reports, our findings
showed PNI holds little prognostic value as a parameter for
long-term surgical outcomes.
Despite extensive validation in a large cohort, retrospec-
tive inclusion and exclusion of patients, the collection of
laboratory data, and the use of prospectively maintained data-
bases, this study has inherent limitations related to its retro-
spective design. We also did not control for other variables
affecting PNI. However, to the best of our knowledge, our study
of the clinical significance of PNI in gastric cancer is the most
comprehensive, to date and includes extensive comparison with
statistically optimized cut-off values and adjustment for poten-
tial confounding factors.
In conclusion, PNI was not associated with cancer recur-
rence in the present study. Although low PNI patients showed
unfavorable prognosis regarding overall survival, their
advanced age may have affected the survival results, despite
adjusting for age in multivariate analysis. The index, never-
theless, exhibits predictive capabilities for the stratification of
patients at increased risk of postoperative morbidity and
mortality. Moreover, this index may be of use in identifying
candidate patients who would benefit from perioperative nutri-
tional support to improve surgical outcomes.
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